首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

1746515

日本伴隨診斷市場報告（按產品與服務、技術（免疫組織化學、聚合酶鍊式反應、原位雜合技術、即時 PCR、基因定序等）、適應症、最終用戶和地區）2025 年至 2033 年

Japan Companion Diagnostics Market Report by Product & Service, Technology (Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing, and Others), Indication, End User, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 122 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本伴隨診斷市場規模達4.495億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到12.085億美元，2025-2033年期間的複合年成長率（CAGR）為11.60%。癌症發生率的上升、個人化醫療需求的日益成長以及新一代定序（NGS）等技術的持續進步，是推動市場成長的主要因素。

伴隨診斷是指幫助醫師確定最適合治療策略的醫學檢測。它們旨在檢測患者組織或血液樣本中存在的特定生物標記物，從而判斷患者是否可能對特定藥物或治療方法產生積極反應。此外，它們還能深入研究患者複雜的生物學特徵和作用機制 (MOA)，幫助醫護人員了解潛在的藥物副作用。伴隨診斷在個人化醫療中得到了廣泛的應用，它考慮到每位患者的獨特特徵，例如其基因組成，以確定最佳治療方案。此外，伴隨診斷在檢測癌症患者的特定基因突變或識別丙型肝炎患者的生物標記方面的應用也日益增多。

日本伴隨診斷市場趨勢：

日本伴隨診斷市場正在經歷顯著成長，主要原因是各種癌症類型發病率的上升，這推動了對更精準、更有針對性的癌症治療的需求。此外，對根據每位患者獨特特徵量身定做的個人化醫療的需求不斷成長，進一步增強了市場前景的樂觀。同時，針對各種感染、心血管、神經系統和發炎疾病的標靶藥物和療法的廣泛應用，也是另一個重要的成長動力。日本伴隨診斷的監管環境良好，越來越多的檢測獲得批准。再加上全球臨床試驗數量的增加，共同推動了市場的成長。診斷技術的持續進步，例如新一代定序 (NGS) 和液體活體組織切片的出現，對於識別先前難以檢測的生物標記至關重要。創新基因組學技術的發展發揮關鍵作用，有助於識別對指導治療決策至關重要的基因突變和生物標記，從而推動市場成長。此外，生物標記在藥物開發中的應用日益增多、對精準醫療的大量投資以及消費者對伴隨診斷益處的認知不斷提高等因素預計將在預測期內為區域市場帶來豐厚的成長機會。

日本伴隨診斷市場細分：

產品與服務洞察：

檢測試劑盒和試劑
軟體和服務

技術洞察：

免疫組織化學（IHC）
聚合酶鍊式反應（PCR）
原位雜合技術（ISH）
即時PCR（RT-PCR）
基因定序
其他

指示見解：

癌症
- 肺癌
- 乳癌
- 大腸直腸癌
- 胃癌
- 黑色素瘤
- 其他
神經系統疾病
傳染病
心血管疾病
其他

最終用戶洞察：

製藥和生物製藥公司
參考實驗室
合約研究組織
其他

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本伴隨診斷市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本伴隨診斷市場有何影響？
日本伴隨診斷市場根據產品和服務的分佈是怎樣的？
日本伴隨診斷市場依技術如何分類？
日本伴隨診斷市場根據適應症的分類是怎樣的？
根據最終用戶，日本伴隨診斷市場是如何分類的？
日本伴隨診斷市場的價值鏈分為哪些階段？
日本伴隨診斷的主要促進因素和挑戰是什麼？
日本伴隨診斷市場的結構是怎麼樣的？主要參與者是誰？
日本伴隨診斷市場的競爭程度如何？

本報告回答的關鍵問題：

日本伴隨診斷市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本伴隨診斷市場有何影響？
日本伴隨診斷市場根據產品和服務的分佈是怎樣的？
日本伴隨診斷市場依技術如何分類？
日本伴隨診斷市場根據適應症的分類是怎樣的？
根據最終用戶，日本伴隨診斷市場是如何分類的？
日本伴隨診斷市場的價值鏈分為哪些階段？
日本伴隨診斷的主要促進因素和挑戰是什麼？
日本伴隨診斷市場的結構是怎麼樣的？主要參與者是誰？
日本伴隨診斷市場的競爭程度如何？

Japan companion diagnostics market size reached USD 449.5 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,208.5 Million by 2033, exhibiting a growth rate (CAGR) of 11.60% during 2025-2033. The rising incidence of cancer, the growing need for personalized medicine, and continuous technological advancements like next-generation sequencing (NGS), are among the primary factors propelling the market growth.

Companion diagnostics refer to medical tests that aid physicians in identifying the most suitable treatment strategy. They are crafted to detect specific biomarkers present in a patient's tissue or blood sample, indicating whether the patient is likely to respond positively to a particular drug or therapeutic approach. Additionally, they delve into the intricate biological profile and mechanism of action (MOA) of patients, assisting healthcare professionals in comprehending potential medication side effects. The widespread application of companion diagnostics is evident in personalized medicine, where it takes into account the distinct characteristics of each patient, such as their genetic composition, to determine the optimal treatment course. Beyond this, there is a growing use of companion diagnostics for examining specific genetic mutations in cancer patients or identifying biomarkers in those with hepatitis C.

Japan Companion Diagnostics Market Trends:

The Japan companion diagnostics market is experiencing significant growth, primarily propelled by the increasing incidence of diverse cancer types, which is fostering the demand for more precise and targeted cancer treatments. Additionally, the escalating demand for personalized medicines, tailored to the unique characteristics of each patient, further contributes to the optimistic market outlook. Simultaneously, the widespread adoption of targeted drugs and therapies addressing various infectious, cardiovascular, neurological, and inflammatory conditions serves as another substantial growth driver. The regulatory landscape for companion diagnostics in Japan is favorable, with an increasing number of tests receiving approvals. This, coupled with the expanding number of global clinical trials, strengthens the market growth. Ongoing advancements in diagnostic technologies, such as the emergence of next-generation sequencing (NGS) and liquid biopsy, are pivotal, enabling the identification of previously challenging-to-detect biomarkers. The development of innovative genomic technologies plays a key role, facilitating the identification of genetic mutations and biomarkers crucial for guiding treatment decisions, thereby fueling market growth. Additionally, factors like the growing use of biomarkers in drug development, substantial investments in precision medicine, and heightened consumer awareness regarding the benefits of companion diagnostics are projected to present lucrative growth opportunities for the regional market over the forecasted period.

Japan Companion Diagnostics Market Segmentation:

Product & Service Insights:

Assays, Kits and Reagents
Software and Services

Technology Insights:

Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
In-situ Hybridization (ISH)
Real-time PCR (RT-PCR)
Gene Sequencing
Others

Indication Insights:

Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Melanoma
- Others
Neurological Diseases
Infectious Diseases
Cardiovascular Diseases
Others

End User Insights:

Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan companion diagnostics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan companion diagnostics market?
What is the breakup of the Japan companion diagnostics market on the basis of product & service?
What is the breakup of the Japan companion diagnostics market on the basis of technology?
What is the breakup of the Japan companion diagnostics market on the basis of indication?
What is the breakup of the Japan companion diagnostics market on the basis of end user?
What are the various stages in the value chain of the Japan companion diagnostics market?
What are the key driving factors and challenges in the Japan companion diagnostics?
What is the structure of the Japan companion diagnostics market and who are the key players?
What is the degree of competition in the Japan companion diagnostics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Companion Diagnostics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Companion Diagnostics Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Companion Diagnostics Market - Breakup by Product & Service

6.1 Assays, Kits and Reagents
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Software and Services
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)

7 Japan Companion Diagnostics Market - Breakup by Technology

7.1 Immunohistochemistry (IHC)
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Polymerase Chain Reaction (PCR)
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 In-situ Hybridization (ISH)
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Real-time PCR (RT-PCR)
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Gene Sequencing
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Others
- 7.6.1 Historical and Current Market Trends (2019-2024)
- 7.6.2 Market Forecast (2025-2033)

8 Japan Companion Diagnostics Market - Breakup by Indication

8.1 Cancer
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Segmentation
  - 8.1.3.1 Lung Cancer
  - 8.1.3.2 Breast Cancer
  - 8.1.3.3 Colorectal Cancer
  - 8.1.3.4 Gastric Cancer
  - 8.1.3.5 Melanoma
  - 8.1.3.6 Others
- 8.1.4 Market Forecast (2025-2033)
8.2 Neurological Diseases
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Infectious Diseases
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Cardiovascular Diseases
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
8.5 Others
- 8.5.1 Historical and Current Market Trends (2019-2024)
- 8.5.2 Market Forecast (2025-2033)

9 Japan Companion Diagnostics Market - Breakup by End User

9.1 Pharmaceutical & Biopharmaceutical Companies
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
9.2 Reference Laboratories
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
9.3 Contract Research Organizations
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
9.4 Others
- 9.4.1 Historical and Current Market Trends (2019-2024)
- 9.4.2 Market Forecast (2025-2033)

10 Japan Companion Diagnostics Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Companion Diagnostics Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis